Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands
Authors:
- Muhammad ShafiqueMSMuhammad Shafique
- Jan WilschutJWJan Wilschut
- Aalzen de HaanAHAalzen de Haan
Abstract
No abstract availableKeywords
Funding Information
- Higher Education Commission (HEC), Government of Pakistan
- HEC-NUFFIC overseas scholarship programme
This publication has 50 references indexed in Scilit:
- Biological challenges and technological opportunities for respiratory syncytial virus vaccine developmentImmunological Reviews, 2010
- Intranasal Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of Intranasal and Subcutaneous Prime-Boost StrategiesClinical and Vaccine Immunology, 2010
- TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severityVaccine, 2009
- Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus diseaseNature Medicine, 2008
- Synthetic CpG oligodeoxynucleotides augment BAFF‐ and APRIL‐mediated immunoglobulin secretionEuropean Journal of Immunology, 2007
- Differential Chemokine Expression following Respiratory Virus Infection Reflects Th1- or Th2-Biased ImmunopathologyJournal of Virology, 2006
- Respiratory Syncytial Virus Infection in Elderly and High-Risk AdultsNew England Journal of Medicine, 2005
- Immune response versus mucosal tolerance to mucosally administered antigensVaccine, 2005
- RETRACTED ARTICLE: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILNature Immunology, 2002
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995